COMMUNIQUÉS West-GlobeNewswire

Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States
06/09/2018
Press Release Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States ................................................. September 6, 2018 - release at 7:30 am CET Sophia Antipolis, [...]
Sensorion Presents Three Posters At The 55th Inner Ear Biology Workshop
06/09/2018
MONTPELLIER, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN ), a biotech company specializing in the treatment of inner ear diseases, today presented three posters at the 55 th Inner Ear [...]
Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States
06/09/2018
SOPHIA ANTIPOLIS, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmic company, announced today that it has previously confidentially submitted a draft [...]
ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
06/09/2018
LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug [...]
ERYTECH tiendra un webcast le 11 septembre 2018 à l’occasion de ses résultats semestriels 2018
06/09/2018
LYON, France, 06 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans [...]
Nicox First Half 2018 Financial Results and Business Update
06/09/2018
NCX 470 Phase 2 clinical study initiated in Q3 2018 NCX 4251 on track for U.S. IND filing in Q1 2019 to enable first-in-human Phase 2 clinical study SOPHIA ANTIPOLIS, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Nicox SA [...]
GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT
06/09/2018
Foster City, Calif. and Mechelen, Belgium; September 6, 2018; 7.00 CET; Regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the randomized, [...]
Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
06/09/2018
PRESS RELEASE : REGULATED INFORMATION Thursday, 6 September 2018, 07:00 CEST BIOCARTIS ANNOUNCES H1 2018 RESULTS Mechelen, Belgium , 6 September 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]
Kiadis Pharma announces two senior management appointments
06/09/2018
Kiadis Pharma announces two senior management appointments Strengthens Senior Management Team with Chief Human Resources Officer and General Counsel and Company Secretary Amsterdam, The Netherlands, September 6, 2018 - [...]
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis
06/09/2018
September 6, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo
06/09/2018
Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic oral solids and Sandoz US [...]
Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering
06/09/2018
SAN DIEGO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the pricing of its offering of $240 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes [...]
Phase 2 Clinical Trial for Venous Leg Ulcers Nears Completion
06/09/2018
BRISBANE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to announce [...]
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06/09/2018
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of Directors approved, [...]
Fluidigm to Participate at Upcoming Investor Events in September
06/09/2018
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s management team will [...]
BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto
05/09/2018
CAMBRIDGE, Mass. and BEIJING, China, Sept. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Avivagen Announces Q3 Financial Results and Proposed Extension of Warrants
05/09/2018
OTTAWA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and [...]
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2018
05/09/2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers ERN France, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Monthly information related to total number of voting rights and shares composing the share [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – 31 août 2018
05/09/2018
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers ERN France, 05 sept. 2018 (GLOBE NEWSWIRE) -- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital [...]

Pages